Upgrades Flow Into Pharma, CDN, and Photonics

Analyst activity picked up on Wednesday, with upgrades and target price lifts spread across healthcare, tech, and materials.

ABBV earned the day's most notable upgrade. AbbVie's consensus moved up after at least one firm raised its rating. The $442 billion pharma giant now sits at 24 Buy ratings. Short interest is minimal at just 1.3% of free float. That tells a clear story: few are betting against it.

AKAM also drew an upgrade. Akamai's consensus target rose to $157.43. Short interest stands at 15% of free float — a meaningful overhang. A positive rating flip here could squeeze nervous shorts.

COHR saw the biggest target price jump in percentage terms among the day's moves. The photonics and optical components maker pushed consensus to $405.71 from $394.62. With a $64 billion market cap and just 5.3% SI, bulls are firmly in control.

ORCL was the day's outlier. Oracle's consensus target dipped slightly to $246.43. No ratings were cut, but the small target trim suggests some price-target trimming after a strong run.

WSM and MSFT both received quiet target lifts. Williams-Sonoma moved to $223.45. Microsoft's average target climbed to $569.56, backed by 53 Buy ratings.